APO Research
Talk to an analyst

APO RESEARCH · REPORT

Anti-Parkinson's Disease Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Anti-Parkinson's Disease Drugs Market Outlook and Growth Opportunities 2026

27 December 2025214 pages

Choose your research edition.

Industry ResearchAnti-Parkinson's Disease Drugs Industry Research Report 2026151 pages · $2,950 USDIndustry Growth & TrendsGlobal Anti-Parkinson's Disease Drugs Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal Anti-Parkinson's Disease Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anti-Parkinson's Disease Drugs Market Outlook and Growth Opportunities 2026214 pages · $4,250 USDMarket Analysis & ForecastGlobal Anti-Parkinson's Disease Drugs Market Analysis and Forecast 2026-2032215 pages · $4,950 USD

Market perspective

The global Anti-Parkinson's Disease Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Anti-Parkinson's Disease Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Anti-Parkinson's Disease Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Anti-Parkinson's Disease Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Anti-Parkinson's Disease Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Anti-Parkinson's Disease Drugs market include Zhejiang Huahai Pharmaceutical Co., Ltd., Tianjin Lisheng Pharmaceutical Co., Ltd., Ningbo Dahongying Pharmaceutical Co., Ltd., Jiangsu Tasly Diyi Pharmaceutical Co., Ltd., Hunan Zhongnan Pharmaceutical Co., Ltd., Hangzhou Guoguang Pharmaceutical Co., Ltd., Guangzhou Kanghe Pharmaceutical Co., Ltd., Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. and Changzhou Kangpu Pharmaceutical Co., Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Anti-Parkinson's Disease Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Anti-Parkinson's Disease Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Anti-Parkinson's Disease Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Anti-Parkinson's Disease Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Anti-Parkinson's Disease Drugs Segment by Company

Zhejiang Huahai Pharmaceutical Co., Ltd.

Tianjin Lisheng Pharmaceutical Co., Ltd.

Ningbo Dahongying Pharmaceutical Co., Ltd.

Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.

Hunan Zhongnan Pharmaceutical Co., Ltd.

Hangzhou Guoguang Pharmaceutical Co., Ltd.

Guangzhou Kanghe Pharmaceutical Co., Ltd.

Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd.

Changzhou Kangpu Pharmaceutical Co., Ltd.

Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd.

Beijing Fuyuan Pharmaceutical Co., Ltd.

Valeant

Teva Pharmaceutical

Stada Arzneimittel

Roche Holding AG

Orion

Novartis

Merck

Lundbeck

Kyowa Kirin

GSK

Endo International plc

Desitin Arzneimittel

Boehringer Ingelheim

Bausch Health

Astellas Pharma

Apokyn

Akorn

Abbvie

Anti-Parkinson's Disease Drugs Segment by Type

Anticholinergics

Dopaminergics

Anti-Parkinson's Disease Drugs Segment by Application

Pharmacy

Hospital

Clinic

Other

Anti-Parkinson's Disease Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Anti-Parkinson's Disease Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Anti-Parkinson's Disease Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Anti-Parkinson's Disease Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Anti-Parkinson's Disease Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-Parkinson's Disease Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anti-Parkinson's Disease Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-Parkinson's Disease Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Anti-Parkinson's Disease Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Anti-Parkinson's Disease Drugs industry.

Chapter 3: Detailed analysis of Anti-Parkinson's Disease Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Anti-Parkinson's Disease Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Anti-Parkinson's Disease Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Anti-Parkinson's Disease Drugs Industry Trends Table 2. Anti-Parkinson's Disease Drugs Industry Drivers Table 3. Anti-Parkinson's Disease Drugs Industry Opportunities and Challenges Table 4. Anti-Parkinson's Disease Drugs Industry Restraints Table 5. Global Anti-Parkinson's Disease Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Anti-Parkinson's Disease Drugs Revenue Share by Company (2021-2026) Table 7. Global Anti-Parkinson's Disease Drugs Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Anti-Parkinson's Disease Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Anti-Parkinson's Disease Drugs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Anti-Parkinson's Disease Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Anti-Parkinson's Disease Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Anti-Parkinson's Disease Drugs Company, Product Type & Application Table 13. Global Anti-Parkinson's Disease Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Anti-Parkinson's Disease Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Anticholinergics Table 18. Significant Companies of Dopaminergics Table 19. Global Anti-Parkinson's Disease Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Anti-Parkinson's Disease Drugs Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Anti-Parkinson's Disease Drugs Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Anti-Parkinson's Disease Drugs Sales Volume Share by Type (2021-2026) Table 23. Global Anti-Parkinson's Disease Drugs Sales Volume Share by Type (2027-2032) Table 24. Global Anti-Parkinson's Disease Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Anti-Parkinson's Disease Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Anti-Parkinson's Disease Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Anti-Parkinson's Disease Drugs Sales Value Share by Type (2021-2026) Table 28. Global Anti-Parkinson's Disease Drugs Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Pharmacy Table 30. Significant Companies of Hospital Table 31. Significant Companies of Clinic Table 32. Significant Companies of Other Table 33. Global Anti-Parkinson's Disease Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Anti-Parkinson's Disease Drugs Sales Volume by Application (2021-2026) & (K Units) Table 35. Global Anti-Parkinson's Disease Drugs Sales Volume by Application (2027-2032) & (K Units) Table 36. Global Anti-Parkinson's Disease Drugs Sales Volume Share by Application (2021-2026) Table 37. Global Anti-Parkinson's Disease Drugs Sales Volume Share by Application (2027-2032) Table 38. Global Anti-Parkinson's Disease Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Anti-Parkinson's Disease Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Anti-Parkinson's Disease Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Anti-Parkinson's Disease Drugs Sales Value Share by Application (2021-2026) Table 42. Global Anti-Parkinson's Disease Drugs Sales Value Share by Application (2027-2032) Table 43. Global Anti-Parkinson's Disease Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Anti-Parkinson's Disease Drugs Sales by Region (2021-2026) & (K Units) Table 45. Global Anti-Parkinson's Disease Drugs Sales Market Share by Region (2021-2026) Table 46. Global Anti-Parkinson's Disease Drugs Sales by Region (2027-2032) & (K Units) Table 47. Global Anti-Parkinson's Disease Drugs Sales Market Share by Region (2027-2032) Table 48. Global Anti-Parkinson's Disease Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Anti-Parkinson's Disease Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Anti-Parkinson's Disease Drugs Sales Value Share by Region (2021-2026) Table 51. Global Anti-Parkinson's Disease Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Anti-Parkinson's Disease Drugs Sales Value Share by Region (2027-2032) Table 53. Global Anti-Parkinson's Disease Drugs Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global Anti-Parkinson's Disease Drugs Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global Anti-Parkinson's Disease Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Global Anti-Parkinson's Disease Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Anti-Parkinson's Disease Drugs Sales by Country (2021-2026) & (K Units) Table 58. Global Anti-Parkinson's Disease Drugs Sales Market Share by Country (2021-2026) Table 59. Global Anti-Parkinson's Disease Drugs Sales by Country (2027-2032) & (K Units) Table 60. Global Anti-Parkinson's Disease Drugs Sales Market Share by Country (2027-2032) Table 61. Global Anti-Parkinson's Disease Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Anti-Parkinson's Disease Drugs Sales Value Market Share by Country (2021-2026) Table 63. Global Anti-Parkinson's Disease Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Anti-Parkinson's Disease Drugs Sales Value Market Share by Country (2027-2032) Table 65. Zhejiang Huahai Pharmaceutical Co., Ltd. Company Information Table 66. Zhejiang Huahai Pharmaceutical Co., Ltd. Business Overview Table 67. Zhejiang Huahai Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Zhejiang Huahai Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio Table 69. Zhejiang Huahai Pharmaceutical Co., Ltd. Recent Development Table 70. Tianjin Lisheng Pharmaceutical Co., Ltd. Company Information Table 71. Tianjin Lisheng Pharmaceutical Co., Ltd. Business Overview Table 72. Tianjin Lisheng Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Tianjin Lisheng Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio Table 74. Tianjin Lisheng Pharmaceutical Co., Ltd. Recent Development Table 75. Ningbo Dahongying Pharmaceutical Co., Ltd. Company Information Table 76. Ningbo Dahongying Pharmaceutical Co., Ltd. Business Overview Table 77. Ningbo Dahongying Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Ningbo Dahongying Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio Table 79. Ningbo Dahongying Pharmaceutical Co., Ltd. Recent Development Table 80. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Company Information Table 81. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Business Overview Table 82. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio Table 84. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Recent Development Table 85. Hunan Zhongnan Pharmaceutical Co., Ltd. Company Information Table 86. Hunan Zhongnan Pharmaceutical Co., Ltd. Business Overview Table 87. Hunan Zhongnan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Hunan Zhongnan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio Table 89. Hunan Zhongnan Pharmaceutical Co., Ltd. Recent Development Table 90. Hangzhou Guoguang Pharmaceutical Co., Ltd. Company Information Table 91. Hangzhou Guoguang Pharmaceutical Co., Ltd. Business Overview Table 92. Hangzhou Guoguang Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Hangzhou Guoguang Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio Table 94. Hangzhou Guoguang Pharmaceutical Co., Ltd. Recent Development Table 95. Guangzhou Kanghe Pharmaceutical Co., Ltd. Company Information Table 96. Guangzhou Kanghe Pharmaceutical Co., Ltd. Business Overview Table 97. Guangzhou Kanghe Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Guangzhou Kanghe Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio Table 99. Guangzhou Kanghe Pharmaceutical Co., Ltd. Recent Development Table 100. Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Company Information Table 101. Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Business Overview Table 102. Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio Table 104. Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Recent Development Table 105. Changzhou Kangpu Pharmaceutical Co., Ltd. Company Information Table 106. Changzhou Kangpu Pharmaceutical Co., Ltd. Business Overview Table 107. Changzhou Kangpu Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Changzhou Kangpu Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio Table 109. Changzhou Kangpu Pharmaceutical Co., Ltd. Recent Development Table 110. Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Company Information Table 111. Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Business Overview Table 112. Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio Table 114. Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Recent Development Table 115. Beijing Fuyuan Pharmaceutical Co., Ltd. Company Information Table 116. Beijing Fuyuan Pharmaceutical Co., Ltd. Business Overview Table 117. Beijing Fuyuan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Beijing Fuyuan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio Table 119. Beijing Fuyuan Pharmaceutical Co., Ltd. Recent Development Table 120. Valeant Company Information Table 121. Valeant Business Overview Table 122. Valeant Anti-Parkinson's Disease Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. Valeant Anti-Parkinson's Disease Drugs Product Portfolio Table 124. Valeant Recent Development Table 125. Teva Pharmaceutical Company Information Table 126. Teva Pharmaceutical Business Overview Table 127. Teva Pharmaceutical Anti-Parkinson's Disease Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. Teva Pharmaceutical Anti-Parkinson's Disease Drugs Product Portfolio Table 129. Teva Pharmaceutical Recent Development Table 130. Stada Arzneimittel Company Information Table 131. Stada Arzneimittel Business Overview Table 132. Stada Arzneimittel Anti-Parkinson's Disease Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 133. Stada Arzneimittel Anti-Parkinson's Disease Drugs Product Portfolio Table 134. Stada Arzneimittel Recent Development Table 135. Roche Holding AG Company Information Table 136. Roche Holding AG Business Overview Table 137. Roche Holding AG Anti-Parkinson's Disease Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 138. Roche Holding AG Anti-Parkinson's Disease Drugs Product Portfolio Table 139. Roche Holding AG Recent Development Table 140. Orion Company Information Table 141. Orion Business Overview Table 142. Orion Anti-Parkinson's Disease Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 143. Orion Anti-Parkinson's Disease Drugs Product Portfolio Table 144. Orion Recent Development Table 145. Novartis Company Information Table 146. Novartis Business Overview Table 147. Novartis Anti-Parkinson's Disease Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 148. Novartis Anti-Parkinson's Disease Drugs Product Portfolio Table 149. Novartis Recent Development Table 150. Merck Company Information Table 151. Merck Business Overview Table 152. Merck Anti-Parkinson's Disease Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 153. Merck Anti-Parkinson's Disease Drugs Product Portfolio Table 154. Merck Recent Development Table 155. Lundbeck Company Information Table 156. Lundbeck Business Overview Table 157. Lundbeck Anti-Parkinson's Disease Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 158. Lundbeck Anti-Parkinson's Disease Drugs Product Portfolio Table 159. Lundbeck Recent Development Table 160. Kyowa Kirin Company Information Table 161. Kyowa Kirin Business Overview Table 162. Kyowa Kirin Anti-Parkinson's Disease Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 163. Kyowa Kirin Anti-Parkinson's Disease Drugs Product Portfolio Table 164. Kyowa Kirin Recent Development Table 165. GSK Company Information Table 166. GSK Business Overview Table 167. GSK Anti-Parkinson's Disease Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 168. GSK Anti-Parkinson's Disease Drugs Product Portfolio Table 169. GSK Recent Development Table 170. Endo International plc Company Information Table 171. Endo International plc Business Overview Table 172. Endo International plc Anti-Parkinson's Disease Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 173. Endo International plc Anti-Parkinson's Disease Drugs Product Portfolio Table 174. Endo International plc Recent Development Table 175. Desitin Arzneimittel Company Information Table 176. Desitin Arzneimittel Business Overview Table 177. Desitin Arzneimittel Anti-Parkinson's Disease Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 178. Desitin Arzneimittel Anti-Parkinson's Disease Drugs Product Portfolio Table 179. Desitin Arzneimittel Recent Development Table 180. Boehringer Ingelheim Company Information Table 181. Boehringer Ingelheim Business Overview Table 182. Boehringer Ingelheim Anti-Parkinson's Disease Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 183. Boehringer Ingelheim Anti-Parkinson's Disease Drugs Product Portfolio Table 184. Boehringer Ingelheim Recent Development Table 185. Bausch Health Company Information Table 186. Bausch Health Business Overview Table 187. Bausch Health Anti-Parkinson's Disease Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 188. Bausch Health Anti-Parkinson's Disease Drugs Product Portfolio Table 189. Bausch Health Recent Development Table 190. Astellas Pharma Company Information Table 191. Astellas Pharma Business Overview Table 192. Astellas Pharma Anti-Parkinson's Disease Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 193. Astellas Pharma Anti-Parkinson's Disease Drugs Product Portfolio Table 194. Astellas Pharma Recent Development Table 195. Apokyn Company Information Table 196. Apokyn Business Overview Table 197. Apokyn Anti-Parkinson's Disease Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 198. Apokyn Anti-Parkinson's Disease Drugs Product Portfolio Table 199. Apokyn Recent Development Table 200. Akorn Company Information Table 201. Akorn Business Overview Table 202. Akorn Anti-Parkinson's Disease Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 203. Akorn Anti-Parkinson's Disease Drugs Product Portfolio Table 204. Akorn Recent Development Table 205. Abbvie Company Information Table 206. Abbvie Business Overview Table 207. Abbvie Anti-Parkinson's Disease Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 208. Abbvie Anti-Parkinson's Disease Drugs Product Portfolio Table 209. Abbvie Recent Development Table 210. Key Raw Materials Table 211. Raw Materials Key Suppliers Table 212. Anti-Parkinson's Disease Drugs Distributors List Table 213. Anti-Parkinson's Disease Drugs Customers List Table 214. Research Programs/Design for This Report Table 215. Authors List of This Report Table 216. Secondary Sources Table 217. Primary Sources List of Figures Figure 1. Anti-Parkinson's Disease Drugs Product Image Figure 2. Global Anti-Parkinson's Disease Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anti-Parkinson's Disease Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Anti-Parkinson's Disease Drugs Sales (2021-2032) & (K Units) Figure 5. Global Anti-Parkinson's Disease Drugs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Anti-Parkinson's Disease Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Anticholinergics Image Figure 10. Dopaminergics Image Figure 11. Global Anti-Parkinson's Disease Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Anti-Parkinson's Disease Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Anti-Parkinson's Disease Drugs Sales Volume Share by Type (2021-2032) Figure 14. Global Anti-Parkinson's Disease Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Anti-Parkinson's Disease Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Anti-Parkinson's Disease Drugs Sales Value Share by Type (2021-2032) Figure 17. Pharmacy Image Figure 18. Hospital Image Figure 19. Clinic Image Figure 20. Other Image Figure 21. Global Anti-Parkinson's Disease Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Anti-Parkinson's Disease Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Anti-Parkinson's Disease Drugs Sales Volume Share by Application (2021-2032) Figure 24. Global Anti-Parkinson's Disease Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Anti-Parkinson's Disease Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Anti-Parkinson's Disease Drugs Sales Value Share by Application (2021-2032) Figure 27. Global Anti-Parkinson's Disease Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 28. Global Anti-Parkinson's Disease Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Anti-Parkinson's Disease Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Anti-Parkinson's Disease Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Anti-Parkinson's Disease Drugs Sales Value (2021-2032) & (US$ Million) Figure 32. North America Anti-Parkinson's Disease Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Anti-Parkinson's Disease Drugs Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Anti-Parkinson's Disease Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Anti-Parkinson's Disease Drugs Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Anti-Parkinson's Disease Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Anti-Parkinson's Disease Drugs Sales Value (2021-2032) & (US$ Million) Figure 38. South America Anti-Parkinson's Disease Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Anti-Parkinson's Disease Drugs Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Anti-Parkinson's Disease Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Anti-Parkinson's Disease Drugs Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Anti-Parkinson's Disease Drugs Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Anticholinergics
  • Dopaminergics
Applications
  • Pharmacy
  • Hospital
  • Clinic
  • Other
Companies covered
  • Zhejiang Huahai Pharmaceutical Co., Ltd.
  • Tianjin Lisheng Pharmaceutical Co., Ltd.
  • Ningbo Dahongying Pharmaceutical Co., Ltd.
  • Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.
  • Hunan Zhongnan Pharmaceutical Co., Ltd.
  • Hangzhou Guoguang Pharmaceutical Co., Ltd.
  • Guangzhou Kanghe Pharmaceutical Co., Ltd.
  • Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd.
  • Changzhou Kangpu Pharmaceutical Co., Ltd.
  • Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd.
  • Beijing Fuyuan Pharmaceutical Co., Ltd.
  • Valeant
  • Teva Pharmaceutical
  • Stada Arzneimittel
  • Roche Holding AG
  • Orion
  • Novartis
  • Merck
  • Lundbeck
  • Kyowa Kirin
  • GSK
  • Endo International plc
  • Desitin Arzneimittel
  • Boehringer Ingelheim
  • Bausch Health
  • Astellas Pharma
  • Apokyn
  • Akorn
  • Abbvie

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Anti-Parkinson's Disease Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Anti-Parkinson's Disease Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Anti-Parkinson's Disease Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Anti-Parkinson's Disease Drugs Market Dynamics
  1. 2.1 Anti-Parkinson's Disease Drugs Industry Trends
  2. 2.2 Anti-Parkinson's Disease Drugs Industry Drivers
  3. 2.3 Anti-Parkinson's Disease Drugs Industry Opportunities and Challenges
  4. 2.4 Anti-Parkinson's Disease Drugs Industry Restraints
3 Anti-Parkinson's Disease Drugs Market by Company
  1. 3.1 Global Anti-Parkinson's Disease Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Anti-Parkinson's Disease Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Anti-Parkinson's Disease Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Anti-Parkinson's Disease Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Anti-Parkinson's Disease Drugs Company Ranking (2024-2026)
  6. 3.6 Global Anti-Parkinson's Disease Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Anti-Parkinson's Disease Drugs Company Product Type and Application
  8. 3.8 Global Anti-Parkinson's Disease Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Anti-Parkinson's Disease Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Anti-Parkinson's Disease Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Anti-Parkinson's Disease Drugs Market by Type
  1. 4.1 Anti-Parkinson's Disease Drugs Type Introduction
  2. 4.1.1 Anticholinergics
  3. 4.1.2 Dopaminergics
  4. 4.2 Global Anti-Parkinson's Disease Drugs Sales Volume by Type
  5. 4.2.1 Global Anti-Parkinson's Disease Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Anti-Parkinson's Disease Drugs Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Anti-Parkinson's Disease Drugs Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Anti-Parkinson's Disease Drugs Sales Value by Type
  9. 4.3.1 Global Anti-Parkinson's Disease Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Anti-Parkinson's Disease Drugs Sales Value by Type (2021-2032)
  11. 4.3.3 Global Anti-Parkinson's Disease Drugs Sales Value Share by Type (2021-2032)
5 Anti-Parkinson's Disease Drugs Market by Application
  1. 5.1 Anti-Parkinson's Disease Drugs Application Introduction
  2. 5.1.1 Pharmacy
  3. 5.1.2 Hospital
  4. 5.1.3 Clinic
  5. 5.1.4 Other
  6. 5.2 Global Anti-Parkinson's Disease Drugs Sales Volume by Application
  7. 5.2.1 Global Anti-Parkinson's Disease Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Anti-Parkinson's Disease Drugs Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Anti-Parkinson's Disease Drugs Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Anti-Parkinson's Disease Drugs Sales Value by Application
  11. 5.3.1 Global Anti-Parkinson's Disease Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Anti-Parkinson's Disease Drugs Sales Value by Application (2021-2032)
  13. 5.3.3 Global Anti-Parkinson's Disease Drugs Sales Value Share by Application (2021-2032)
6 Anti-Parkinson's Disease Drugs Regional Sales and Value Analysis
  1. 6.1 Global Anti-Parkinson's Disease Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Anti-Parkinson's Disease Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Anti-Parkinson's Disease Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Anti-Parkinson's Disease Drugs Sales by Region (2027-2032)
  5. 6.3 Global Anti-Parkinson's Disease Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Anti-Parkinson's Disease Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Anti-Parkinson's Disease Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Anti-Parkinson's Disease Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Anti-Parkinson's Disease Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Anti-Parkinson's Disease Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Anti-Parkinson's Disease Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Anti-Parkinson's Disease Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Anti-Parkinson's Disease Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Anti-Parkinson's Disease Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Anti-Parkinson's Disease Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Anti-Parkinson's Disease Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Anti-Parkinson's Disease Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Anti-Parkinson's Disease Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Anti-Parkinson's Disease Drugs Sales Value Share by Country, 2025 VS 2032
7 Anti-Parkinson's Disease Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Anti-Parkinson's Disease Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Anti-Parkinson's Disease Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Anti-Parkinson's Disease Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Anti-Parkinson's Disease Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Anti-Parkinson's Disease Drugs Sales by Country (2027-2032)
  6. 7.4 Global Anti-Parkinson's Disease Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Anti-Parkinson's Disease Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Anti-Parkinson's Disease Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Anti-Parkinson's Disease Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Anti-Parkinson's Disease Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Anti-Parkinson's Disease Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Zhejiang Huahai Pharmaceutical Co., Ltd.
  2. 8.1.1 Zhejiang Huahai Pharmaceutical Co., Ltd. Company Information
  3. 8.1.2 Zhejiang Huahai Pharmaceutical Co., Ltd. Business Overview
  4. 8.1.3 Zhejiang Huahai Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Zhejiang Huahai Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
  6. 8.1.5 Zhejiang Huahai Pharmaceutical Co., Ltd. Recent Developments
  7. 8.2 Tianjin Lisheng Pharmaceutical Co., Ltd.
  8. 8.2.1 Tianjin Lisheng Pharmaceutical Co., Ltd. Company Information
  9. 8.2.2 Tianjin Lisheng Pharmaceutical Co., Ltd. Business Overview
  10. 8.2.3 Tianjin Lisheng Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Tianjin Lisheng Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
  12. 8.2.5 Tianjin Lisheng Pharmaceutical Co., Ltd. Recent Developments
  13. 8.3 Ningbo Dahongying Pharmaceutical Co., Ltd.
  14. 8.3.1 Ningbo Dahongying Pharmaceutical Co., Ltd. Company Information
  15. 8.3.2 Ningbo Dahongying Pharmaceutical Co., Ltd. Business Overview
  16. 8.3.3 Ningbo Dahongying Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Ningbo Dahongying Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
  18. 8.3.5 Ningbo Dahongying Pharmaceutical Co., Ltd. Recent Developments
  19. 8.4 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.
  20. 8.4.1 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Company Information
  21. 8.4.2 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Business Overview
  22. 8.4.3 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
  24. 8.4.5 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Recent Developments
  25. 8.5 Hunan Zhongnan Pharmaceutical Co., Ltd.
  26. 8.5.1 Hunan Zhongnan Pharmaceutical Co., Ltd. Company Information
  27. 8.5.2 Hunan Zhongnan Pharmaceutical Co., Ltd. Business Overview
  28. 8.5.3 Hunan Zhongnan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Hunan Zhongnan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
  30. 8.5.5 Hunan Zhongnan Pharmaceutical Co., Ltd. Recent Developments
  31. 8.6 Hangzhou Guoguang Pharmaceutical Co., Ltd.
  32. 8.6.1 Hangzhou Guoguang Pharmaceutical Co., Ltd. Company Information
  33. 8.6.2 Hangzhou Guoguang Pharmaceutical Co., Ltd. Business Overview
  34. 8.6.3 Hangzhou Guoguang Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Hangzhou Guoguang Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
  36. 8.6.5 Hangzhou Guoguang Pharmaceutical Co., Ltd. Recent Developments
  37. 8.7 Guangzhou Kanghe Pharmaceutical Co., Ltd.
  38. 8.7.1 Guangzhou Kanghe Pharmaceutical Co., Ltd. Company Information
  39. 8.7.2 Guangzhou Kanghe Pharmaceutical Co., Ltd. Business Overview
  40. 8.7.3 Guangzhou Kanghe Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Guangzhou Kanghe Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
  42. 8.7.5 Guangzhou Kanghe Pharmaceutical Co., Ltd. Recent Developments
  43. 8.8 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd.
  44. 8.8.1 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Company Information
  45. 8.8.2 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Business Overview
  46. 8.8.3 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
  48. 8.8.5 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Recent Developments
  49. 8.9 Changzhou Kangpu Pharmaceutical Co., Ltd.
  50. 8.9.1 Changzhou Kangpu Pharmaceutical Co., Ltd. Company Information
  51. 8.9.2 Changzhou Kangpu Pharmaceutical Co., Ltd. Business Overview
  52. 8.9.3 Changzhou Kangpu Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Changzhou Kangpu Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
  54. 8.9.5 Changzhou Kangpu Pharmaceutical Co., Ltd. Recent Developments
  55. 8.10 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd.
  56. 8.10.1 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Company Information
  57. 8.10.2 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Business Overview
  58. 8.10.3 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
  60. 8.10.5 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Recent Developments
  61. 8.11 Beijing Fuyuan Pharmaceutical Co., Ltd.
  62. 8.11.1 Beijing Fuyuan Pharmaceutical Co., Ltd. Company Information
  63. 8.11.2 Beijing Fuyuan Pharmaceutical Co., Ltd. Business Overview
  64. 8.11.3 Beijing Fuyuan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Beijing Fuyuan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
  66. 8.11.5 Beijing Fuyuan Pharmaceutical Co., Ltd. Recent Developments
  67. 8.12 Valeant
  68. 8.12.1 Valeant Company Information
  69. 8.12.2 Valeant Business Overview
  70. 8.12.3 Valeant Anti-Parkinson's Disease Drugs Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Valeant Anti-Parkinson's Disease Drugs Product Portfolio
  72. 8.12.5 Valeant Recent Developments
  73. 8.13 Teva Pharmaceutical
  74. 8.13.1 Teva Pharmaceutical Company Information
  75. 8.13.2 Teva Pharmaceutical Business Overview
  76. 8.13.3 Teva Pharmaceutical Anti-Parkinson's Disease Drugs Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Teva Pharmaceutical Anti-Parkinson's Disease Drugs Product Portfolio
  78. 8.13.5 Teva Pharmaceutical Recent Developments
  79. 8.14 Stada Arzneimittel
  80. 8.14.1 Stada Arzneimittel Company Information
  81. 8.14.2 Stada Arzneimittel Business Overview
  82. 8.14.3 Stada Arzneimittel Anti-Parkinson's Disease Drugs Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Stada Arzneimittel Anti-Parkinson's Disease Drugs Product Portfolio
  84. 8.14.5 Stada Arzneimittel Recent Developments
  85. 8.15 Roche Holding AG
  86. 8.15.1 Roche Holding AG Company Information
  87. 8.15.2 Roche Holding AG Business Overview
  88. 8.15.3 Roche Holding AG Anti-Parkinson's Disease Drugs Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Roche Holding AG Anti-Parkinson's Disease Drugs Product Portfolio
  90. 8.15.5 Roche Holding AG Recent Developments
  91. 8.16 Orion
  92. 8.16.1 Orion Company Information
  93. 8.16.2 Orion Business Overview
  94. 8.16.3 Orion Anti-Parkinson's Disease Drugs Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Orion Anti-Parkinson's Disease Drugs Product Portfolio
  96. 8.16.5 Orion Recent Developments
  97. 8.17 Novartis
  98. 8.17.1 Novartis Company Information
  99. 8.17.2 Novartis Business Overview
  100. 8.17.3 Novartis Anti-Parkinson's Disease Drugs Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Novartis Anti-Parkinson's Disease Drugs Product Portfolio
  102. 8.17.5 Novartis Recent Developments
  103. 8.18 Merck
  104. 8.18.1 Merck Company Information
  105. 8.18.2 Merck Business Overview
  106. 8.18.3 Merck Anti-Parkinson's Disease Drugs Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Merck Anti-Parkinson's Disease Drugs Product Portfolio
  108. 8.18.5 Merck Recent Developments
  109. 8.19 Lundbeck
  110. 8.19.1 Lundbeck Company Information
  111. 8.19.2 Lundbeck Business Overview
  112. 8.19.3 Lundbeck Anti-Parkinson's Disease Drugs Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Lundbeck Anti-Parkinson's Disease Drugs Product Portfolio
  114. 8.19.5 Lundbeck Recent Developments
  115. 8.20 Kyowa Kirin
  116. 8.20.1 Kyowa Kirin Company Information
  117. 8.20.2 Kyowa Kirin Business Overview
  118. 8.20.3 Kyowa Kirin Anti-Parkinson's Disease Drugs Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 Kyowa Kirin Anti-Parkinson's Disease Drugs Product Portfolio
  120. 8.20.5 Kyowa Kirin Recent Developments
  121. 8.21 GSK
  122. 8.21.1 GSK Company Information
  123. 8.21.2 GSK Business Overview
  124. 8.21.3 GSK Anti-Parkinson's Disease Drugs Sales, Value and Gross Margin (2021-2026)
  125. 8.21.4 GSK Anti-Parkinson's Disease Drugs Product Portfolio
  126. 8.21.5 GSK Recent Developments
  127. 8.22 Endo International plc
  128. 8.22.1 Endo International plc Company Information
  129. 8.22.2 Endo International plc Business Overview
  130. 8.22.3 Endo International plc Anti-Parkinson's Disease Drugs Sales, Value and Gross Margin (2021-2026)
  131. 8.22.4 Endo International plc Anti-Parkinson's Disease Drugs Product Portfolio
  132. 8.22.5 Endo International plc Recent Developments
  133. 8.23 Desitin Arzneimittel
  134. 8.23.1 Desitin Arzneimittel Company Information
  135. 8.23.2 Desitin Arzneimittel Business Overview
  136. 8.23.3 Desitin Arzneimittel Anti-Parkinson's Disease Drugs Sales, Value and Gross Margin (2021-2026)
  137. 8.23.4 Desitin Arzneimittel Anti-Parkinson's Disease Drugs Product Portfolio
  138. 8.23.5 Desitin Arzneimittel Recent Developments
  139. 8.24 Boehringer Ingelheim
  140. 8.24.1 Boehringer Ingelheim Company Information
  141. 8.24.2 Boehringer Ingelheim Business Overview
  142. 8.24.3 Boehringer Ingelheim Anti-Parkinson's Disease Drugs Sales, Value and Gross Margin (2021-2026)
  143. 8.24.4 Boehringer Ingelheim Anti-Parkinson's Disease Drugs Product Portfolio
  144. 8.24.5 Boehringer Ingelheim Recent Developments
  145. 8.25 Bausch Health
  146. 8.25.1 Bausch Health Company Information
  147. 8.25.2 Bausch Health Business Overview
  148. 8.25.3 Bausch Health Anti-Parkinson's Disease Drugs Sales, Value and Gross Margin (2021-2026)
  149. 8.25.4 Bausch Health Anti-Parkinson's Disease Drugs Product Portfolio
  150. 8.25.5 Bausch Health Recent Developments
  151. 8.26 Astellas Pharma
  152. 8.26.1 Astellas Pharma Company Information
  153. 8.26.2 Astellas Pharma Business Overview
  154. 8.26.3 Astellas Pharma Anti-Parkinson's Disease Drugs Sales, Value and Gross Margin (2021-2026)
  155. 8.26.4 Astellas Pharma Anti-Parkinson's Disease Drugs Product Portfolio
  156. 8.26.5 Astellas Pharma Recent Developments
  157. 8.27 Apokyn
  158. 8.27.1 Apokyn Company Information
  159. 8.27.2 Apokyn Business Overview
  160. 8.27.3 Apokyn Anti-Parkinson's Disease Drugs Sales, Value and Gross Margin (2021-2026)
  161. 8.27.4 Apokyn Anti-Parkinson's Disease Drugs Product Portfolio
  162. 8.27.5 Apokyn Recent Developments
  163. 8.28 Akorn
  164. 8.28.1 Akorn Company Information
  165. 8.28.2 Akorn Business Overview
  166. 8.28.3 Akorn Anti-Parkinson's Disease Drugs Sales, Value and Gross Margin (2021-2026)
  167. 8.28.4 Akorn Anti-Parkinson's Disease Drugs Product Portfolio
  168. 8.28.5 Akorn Recent Developments
  169. 8.29 Abbvie
  170. 8.29.1 Abbvie Company Information
  171. 8.29.2 Abbvie Business Overview
  172. 8.29.3 Abbvie Anti-Parkinson's Disease Drugs Sales, Value and Gross Margin (2021-2026)
  173. 8.29.4 Abbvie Anti-Parkinson's Disease Drugs Product Portfolio
  174. 8.29.5 Abbvie Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Anti-Parkinson's Disease Drugs Value Chain Analysis
  2. 9.1.1 Anti-Parkinson's Disease Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Anti-Parkinson's Disease Drugs Sales Mode & Process
  6. 9.2 Anti-Parkinson's Disease Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Anti-Parkinson's Disease Drugs Distributors
  9. 9.2.3 Anti-Parkinson's Disease Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst